159. 色素性乾皮症 Xeroderma pigmentosum Clinical trials / Disease details

臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

diseases per page:

Showing 1 to 10 of 11 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05370235 (ClinicalTrials.gov)	March 28, 2022	21/4/2022	A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma PigmentosumC ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Xeroderma Pigmentosum	Drug: Afamelanotide	Clinuvel Europe Limited	NULL	Recruiting	18 Years	75 Years	All	6	Phase 2	Belgium;Spain
2	EUCTR2021-001419-10-ES (EUCTR)	31/01/2022	17/11/2021	Study to evaluate the safety and the efficacy of the photoprotective drug, afamelanotide in patients ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Patients with Xeroderma PigmentosumC and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: SCENESSE Product Name: Afamelanotide (16 mg implant)	CLINUVEL EUROPE LIMITED	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Belgium;Spain
3	NCT05159752 (ClinicalTrials.gov)	October 19, 2021	9/11/2021	A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum( ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Xeroderma Pigmentosum	Drug: Afamelanotide	Clinuvel Europe Limited	NULL	Recruiting	18 Years	75 Years	All	6	Phase 2	Germany
4	EUCTR2021-003642-20-DE (EUCTR)	27/09/2021	09/07/2021	Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients withXeroderma Pigmentosum (XP ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous I ...	xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases ...	Trade Name: SCENESSE Product Name: SCENESSE INN or Proposed INN: Afamelanotide	CLINUVEL EUROPE LTD	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Germany
5	EUCTR2019-000597-34-DE (EUCTR)	01/06/2021	11/01/2021	Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients withXeroderma Pigmentosum (XP ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous I ...	xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases ...	Trade Name: SCENESSE Product Name: SCENESSE INN or Proposed INN: AFAMELANOTIDE	CLINUVEL EUROPE LIMITED	NULL	Not Recruiting			Female: yes Male: yes	6	Phase 2	Germany
6	NCT04500548 (ClinicalTrials.gov)	January 28, 2021	4/8/2020	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescen ...	3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Com ...	Constitutional Mismatch Repair Deficiency Syndrome;Hematopoietic and Lymphoid Cell Neoplasm;Lynch Sy ...	Procedure: Biospecimen Collection;Biological: Ipilimumab;Biological: Nivolumab	National Cancer Institute (NCI)	NULL	Withdrawn	12 Months	25 Years	All	0	Phase 1	United States;Canada
7	EUCTR2010-022968-13-ES (EUCTR)	22/03/2011	25/01/2011	Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cánc ...	Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cánc ...	Cáncer de mama avanzado. MedDRA version: 13;Level: LLT;Classification code 10006204;Term: Carcinoma ...	Trade Name: YONDELIS 0,25 mg polvo para concentrado para solución para perfusión INN or Proposed INN: ...	PharmaMar S.A. Sociedad Unipersonal	NULL	Not Recruiting			Female: yes Male: no	100	Phase 2	Belgium;Spain
8	EUCTR2010-022968-13-BE (EUCTR)	16/03/2011	04/01/2011	Study of the medicinal product Trabectedin in Patients with AdvancedBreast Carcinoma.	Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Recepto ...	Advanced Breast Carcinoma MedDRA version: 14.0;Level: LLT;Classification code 10006204;Term: Breast ...	Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion. INN or Proposed INN: tr ...	Pharma Mar, S.A. Sociedad Unipersonal	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	Spain;Belgium
9	NCT00002811 (ClinicalTrials.gov)	July 1996	1/11/1999	T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With ...	A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPO ...	Precancerous Condition	Drug: liposomal T4N5 lotion	Applied Genetics	NULL	Active, not recruiting	2 Years	60 Years	Both	30	Phase 3	United States;Germany;United Kingdom
10	NCT00025012 (ClinicalTrials.gov)	June 1991	11/10/2001	Isotretinoin in Preventing Skin Cancer	Use Of Isotretinion For Prevention Of Skin Cancer In Patients With Xeroderma PigmentosumOr Nevoid Ba ...	Melanoma (Skin);Non-melanomatous Skin Cancer	Drug: isotretinoin	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	2 Years	N/A	Both		N/A	United States

First Previous1 2Next Last